|Bid||1.90 x 3200|
|Ask||1.92 x 2900|
|Day's Range||1.8700 - 1.9350|
|52 Week Range||1.1500 - 2.7500|
|Beta (3Y Monthly)||2.78|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.38|
NEW YORK, Feb. 15, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
With headlines popping up left and right, news surrounding these innovative companies in the healthcare industry has worked to attract investors looking for potential opportunities in the space. As an industry predicated on improving the quality of life for consumers, Premier Health Group (OTC:PHGRF) (CSE:PHGI), Novavax Inc (NVAX), Trevena Inc (TRVN), and Teladoc Health Inc (TDOC) represent four healthcare companies determined to invest in the betterment of the global health market. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing nuanced approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network.
HENDERSON, NV / ACCESSWIRE / January 21, 2019 / Biotechnology companies have seen a ton of interest from Big Pharma so far in 2019. While it's not easy to project who may be next, there are several biotech ...
HENDERSON, NV / ACCESSWIRE / January 17, 2019 / Below are some incredible opportunities in the market today. Gopher Protocol Inc. (GOPH) , is an absolutely fascinating company that was trading has a 52-week ...
NEW YORK, NY / ACCESSWIRE / January 14, 2019 / U.S. equities posted strong weekly gains, however, stock closed lower for the day on Friday on concerns over an ongoing U.S. government shutdown and worries ...
Novavax Rose Due to Positive NanoFlu Vaccine Results ## Share price movements On January 3, Novavax (NVAX) issued a press release announcing positive top-line results from the Phase 2 trial comparing the safety and immunogenicity of its multiple NanoFlu vaccine formulations. Two influenza vaccines are already licensed in the United States for healthy, older adults. According to the press release, the company plans to schedule an end-of-Phase 2 meeting with the FDA and start the pivotal Phase 3 trial for the vaccine in 2019. Novavax expects the FDA to allow the company to pursue an accelerated approval pathway for NanoFlu, which would allow it to secure a US license in the coming years. After the announcement, Novavax reported a 3.55% rise in the share prices from $1.97 on January 2 to $2.04 on January 3. The company closed at $2.14 on January 4, which is 4.90% higher compared to the previous closing price. Based on its closing price on January 4, the company reported returns of 13.83% in the last week, -2.28% in the last month, and 2.39% in the last quarter. Novavax also reported returns of 56.20% in the second half of 2018, 58.52% in 2018, and 16.30% YTD. ## Analysts’ recommendations and target price On January 7, analysts’ consensus 12-month recommendation for Novavax is a “buy.” The 12-month consensus target price for the company is $4.5, which is 110.28% higher than its closing price on January 4. The highest target price estimate for the company is $10, while the lowest target price estimate is $1.5. Among the eight analysts covering Novavax on January 7, three recommended a “strong buy,” three recommended a “buy,” and two recommended a “hold.”
Novavax Inc. is starting 2019 on a high note, reporting positive phase 2 results for its flu vaccine candidate Thursday in what is expected to be a critical year for the Gaithersburg biotech. The clinical trial for NanoFlu, which compared elderly adults’ immune responses to two flu vaccines on the market, found that its formulations were well-tolerated — and 50 percent more effective than market leader Fluzone High-Dose. The results sent Novavax (NASDAQ: NVAX) shares up more than 6 percent Thursday and Friday.
CORAL GABLES, FL / ACCESSWIRE / January 4, 2019 / The healthcare industry is predicated on the notion that as diseases become more advanced and difficult to treat, companies responsible for creating treatment options will rise to the occasion to assist patients suffering from said ailments. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Synergy Pharmaceuticals Inc (SGYP), Novavax Inc (NVAX), and Epizyme Inc (EPZM) are 4 healthcare stocks representing companies invested in creating the best quality treatments for their patients. Premier Health Group (OTC:PHGRF) (CSE:PHGI) opened Friday with the Company's shares trading at $0.63 per share, well above the $0.53 close back in October, as well as steadily ahead of $0.59 per share price point from early last month.
HENDERSON, NV / ACCESSWIRE / January 4, 2019 / Biotech companies could be in store for a big 2019, and investors are starting to take notice. The stocks we are highlighting today all look poised for a ...
Here's a roundup of top developments in the biotech space over the last 24 hours. None of the biotech stocks reached 52-week highs Thursday. Down In The Dumps (Biotech Stocks Hitting 52-week lows on Jan. ...
Novavax Inc. shares soared up to 12% higher in after-hours trading Thursday, when the company announced positive results for its NanoFlu flu vaccine candidate. "These confirmatory data from the second clinical trial of NanoFlu further justify continued rapid development of an improved vaccine," Novavax executive Gregory Glenn said in Thursday's news release. Novavax disclosed that it will meet with the Food and Drug Administration in the first half of this year to discuss the results and plan for a Phase 3 trial of the vaccine, which the company said it expects to launch this year. The NanoFlu vaccine has shown strong results in the past against the H3N2 flu strain, which has been a problem for standard vaccines; the Phase 2 study focused on usage in older adults. After closing with a 3.6% gain at $2.04, shares neared $2.30 in late trading after the announcement.
The trial compared the safety and immune responses of various quadrivalent formulations of NanoFlu, with or without Novavax’ Matrix-M™ adjuvant, with two U.S.-licensed influenza vaccines in 1,375 healthy adults 65 years of age and older.
GAITHERSBURG, Md., Jan. 02, 2019 -- Novavax, Inc. (Nasdaq:NVAX) today announced that it will present at the 37th Annual J.P. Morgan Healthcare Conference. Presentation details.
CORAL GABLES, FL / ACCESSWIRE / January 2, 2019 / As we dive, head-first into the new year, companies in the healthcare sector are working tirelessly to create and implement nuanced methods for treating patients with a myriad of diseases and ailments. From data-based care solutions to improved treatment options, Premier Health Group (OTC:PHGRF) (CSE:PHGI), Novavax Inc (NASDAQ: NVAX), Rite Aid Corporation (NYSE:RAD), and Bausch Health Companies Inc (NYSE: BHC) are 4 healthcare stocks representing companies prepared to innovate towards the future of the industry. Premier Health Group (OTC:PHGRF) (CSE:PHGI), a company dominating the telehealth sector of the healthcare industry, enjoyed a strong month of bullish trading back in December, with Company shares soaring well above the 30% mark in a 30-day period.